Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07475546

Combination Gerotherapeutic Interventions for Healthspan Improvement

This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Healthspan Improvement Aging Longevity

Age range

60 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

AgelessRx

Ann Arbor, Michigan, 48104, United States

About this study

The two main study objectives are 1) To evaluate the impact of different combinations of gerotherapeutics on measures of muscle, cognitive, and immune function, & 2) To assess the impact of the combinatorial gerotherapeutics on sleep measures, perceived quality of life, and longevity biomarkers. Potential subjects will be recruited utilizing email and social media-based methods. They will be screened for eligibility and enrolled in the study upon obtaining informed consent. All groups will complete DEXA scans, V02 Max tests, Creyos cognitive assessments, Edifice Health's iAge tests, iollo at-home blood testing kits, routine blood-work, and the following standardized survey questionnaires: ISQ (Immune Status Questionnaire), SF-36 (Quality of Life), RAPA (Rapid Assessment of Physical Activity), and SQS (Sleep Quality Survey). Subjects will set up Oura data-tracking for health biometric data with study staff assistance. Intervention group participants will also receive a guided meditation program and structured exercise program to follow throughout the study. In contrast, participants in the control group will engage in a standard exercise regimen (150 minutes per week) and listen to a neutral podcast designed to control for time and attention.

Participants will be evaluated at baseline and study end for measures of muscle function (by DEXA scan of muscle mass and the VO2 max test to measure endurance capacity using a formal test and/or Oura ring estimate), cognitive function (by Creyos cognitive tests via web browser), immune function (by iAge and CD4+ : CD8+ ratio/lymphocyte : neutrophil ratio with Immune Status Questionnaire (ISQ) supplementation), SF-36 Quality of Life (SF-36 QoL) survey scores, PhenoAge (from blood biomarkers obtained from routine safety labs, detailed below), activity levels (RAPA questionnaire, Oura ring), metabolic health measures from routine and at-home blood tests, sleep improvements evaluated through Oura wearable device sleep quality and quantity as well as the Sleep Quality Survey (SQS), as well as other health indicators from Oura wearable data between baseline and study end. To ensure robustness of outcome measures, two measurements of each item 1 week apart will be used at baseline and again at study end for all measures except for DEXA scan, V02 max formal test and Oura ring estimate, iAge and iollo kits, which will be used once at the beginning and once at the end of the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New, existing, or prospective AgelessRx patient
  • Adults (60-80 years of age)
  • Any sex
  • Any ethnicity
  • Willingness to provide informed consent and complete study assessments/procedures
  • Willingness to attend virtual meeting check-ins/follow-ups
  • Willingness and eligibility to take all medications used in this study
  • Has at-risk indicators for decline on measures of cognitive, immune, and muscle function, as indicated by a combination of BMI of 26-30; SF36 score below the validated central tendency for 2 of: physical function, physical role limitations, energy, pain; final ISQ scores of <6; individuals that report brain fog or difficulty with mental clarity; pre-diabetic, or other comorbidities that result in reduced overall health functioning as determined by a physician

Exclusion criteria

  • Pregnant or breastfeeding individuals
  • History of severe adverse reactions to study medications
  • Significant psychiatric illness that may affect participation
  • Determination of ineligibility for a study medication by AgelessRx medical team
  • Concurrent participation in other conflicting clinical trials

Treatment and study plan

Rapamycin

Drug

In the comprehensive therapy group, participants will start LDR at 2mg once per week and titrate up weekly to 6mg once per week.

Other names: sirolimus, low-dose rapamycin (LDR)

Naltrexone

Drug

In both intervention groups, participants will start LDN at 1.5mg once daily and titrate up each week to 4.5mg daily.

Other names: low-dose naltrexone (LDN)

metformin

Drug

In both intervention groups, participants will take Metformin at 500mg daily.

NAD+

Drug

In both intervention groups, NAD+ will be taken as a nasal spray of 30mg/day.

Other names: nicotinamide adenine dinucleotide (NAD+)

GSH

Drug

In the comprehensive therapy group, GSH will be taken as a topical patch for 4 hrs, once per week.

Other names: Glutathione

Infinite Supplement

Dietary Supplement

Participants in the comprehensive therapy group will take the Infinite supplement once daily. The Infinite supplement is a proprietary blend of seven putative geroprotective compounds implicated in enhancing cellular function critical for managing cellular damage accumulation prevention of age-related decline (including Alpha ketoglutarate, Quercetin, Glucosamine, Carnosine, Pterostilbene, Astaxanthin, and Curcumin)

Placebo/Control

Drug

In the control cohort, participants will take Vitamin C (1x/day) and Vitamin E (1x/week) as placebo agents.

B12

Dietary Supplement

In both intervention groups, participants will take vitamin B12 once daily.

Other names: Methylcobalamin

Intervention: Guided Meditation Program

Behavioral

Intervention group participants will follow a daily, app-based meditation program for 20 minutes a day.

Control: Podcast Listening Activity

Behavioral

Control participants will listen to a neutral podcast for 20 minutes a day designed to control for time and attention.

Control: Standard Exercise Regimen

Behavioral

Control group participants will engage in a standard exercise regimen (150 minutes of aerobic activity such as walking per week).

Intervention: Structured Exercise Program

Behavioral

Intervention group participants will follow a structured daily exercise program including resistance training and a recommendation for 150 minutes of aerobic activity (e.g., walking) per week.

Primary outcomes

  1. Change in cardiorespiratory fitness measured by maximal oxygen uptake (VO₂ max)

    Time frame: 3 months

    Maximal oxygen uptake (VO₂ max) will be assessed using standardized cardiopulmonary exercise testing. This assessment will be conducted once at baseline and once at the 3-month follow-up. The outcome will be the change in VO₂ max from baseline to 3 months.

  2. Change in cognitive performance measured by Creyos Cognitive Test composite score

    Time frame: 3 months

    Cognitive performance will be assessed using the Creyos online cognitive assessment platform. Assessments will be conducted twice at baseline and twice during the final study period, with measurements occurring at least 7 days apart. Scores from the two assessments at each timepoint will be averaged to determine the baseline and endpoint values. The outcome will be the change in the overall composite cognitive performance score from baseline to 3 months.

  3. Change in systemic chronic inflammation measured by iAge index score

    Time frame: 3 months

    Immune function will be assessed via systemic chronic inflammation using the iAge Index Score derived from blood biomarkers. This assessment will be conducted once at baseline and once at the 3-month follow-up. The outcome will be the change in iAge index score from baseline to 3 months.

  4. Change in lean body mass measured by dual-energy X-ray absorptiometry (DEXA)

    Time frame: 3 months

    Lean body mass will be assessed using dual-energy X-ray absorptiometry (DEXA). This assessment will be conducted once at baseline and once at the 3-month follow-up. The outcome will be the change in total lean body mass from baseline to 3 months.

Secondary outcomes

  1. Change in total sleep time measured using Oura wearable device

    Time frame: 3 months

    Total sleep time will be assessed using sleep data collected from the Oura Ring wearable device. Total sleep time represents the total duration of sleep obtained during the primary sleep period each night. Total sleep time will be measured twice at baseline and twice during the final study period, with measurements occurring at least 7 days apart. Values from each assessment period will be averaged to determine the baseline and 3-month outcome values. The outcome will be the change in average nightly total sleep time from baseline to 3 months.

  2. Change in health-related quality of life measured by the Short Form Health Survey (SF-36)

    Time frame: 3 months

    Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. Assessments will be conducted twice at baseline and twice at the 3-month follow-up, with measurements occurring at least 7 days apart. Values from the two assessments at each timepoint will be averaged. The outcome will be the change in overall SF-36 score from baseline to 3 months.

  3. Change in biological age estimated from blood-based biomarker panels

    Time frame: 3 months

    Biological age will be estimated using biomarker panels derived from the iollo home testing kit. his assessment will be conducted once at baseline and once at the 3-month follow-up. The outcome will be the change in estimated biological age from baseline to 3 months.

  4. Change in sleep quality measured by the Sleep Quality Scale (SQS)

    Time frame: 3 months

    Sleep quality will be assessed using the Sleep Quality Scale (SQS), a validated self-report instrument ranging from 0 to 84, where higher scores indicate worse sleep quality. Assessments will be conducted twice at baseline and twice at the 3-month follow-up, with measurements occurring at least 7 days apart. Values from the two assessments at each timepoint will be averaged. The outcome will be the change in overall sleep score from baseline to 3 months.

  5. Change in physical activity measured by the Rapid Assessment of Physical Activity (RAPA) questionnaire

    Time frame: 3 months

    Physical activity will be assessed using the Rapid Assessment of Physical Activity (RAPA) questionnaire. Scores range from 1 to 7, with higher scores indicating greater levels of physical activity. Assessments will be conducted twice at baseline and twice at the 3-month follow-up, with measurements occurring at least 7 days apart. Values from the two assessments at each timepoint will be averaged. The outcome will be the change in physical activity score from baseline to 3 months.

  6. Change in self-reported immune function measured by the Immune Status Questionnaire (ISQ)

    Time frame: 3 months

    Self-reported immune function will be assessed using the Immune Status Questionnaire (ISQ), a validated self-report instrument that evaluates the frequency of immune-related symptoms (e.g., colds, fever, cough, and other infection-related complaints). The ISQ produces a total score ranging from 0 to 10, with higher scores indicating better perceived immune functioning. Assessments will be conducted twice at baseline and twice at the 3-month follow-up, with measurements occurring at least 7 days apart. Values from the two assessments at each timepoint will be averaged. The outcome will be the change in ISQ total score from baseline to 3 months.

  7. Change from baseline to 3 months in hemoglobin A1c

    Time frame: 3 months

    Hemoglobin A1c (HbA1c) will be measured from venous blood samples collected during routine laboratory testing. HbA1c reflects average blood glucose levels over approximately the prior 2-3 months. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Values from each timepoint will be averaged.

  8. Change from baseline to 3 months in fasting insulin concentration

    Time frame: 3 months

    Fasting insulin will be measured from venous blood samples collected during routine laboratory testing. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  9. Change from baseline to 3 months in high-sensitivity C-reactive protein (hs-CRP)

    Time frame: 3 months

    High-sensitivity C-reactive protein (hs-CRP) will be measured from venous blood samples as a marker of systemic inflammation. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  10. Change from baseline to 3 months in low-density lipoprotein cholesterol (LDL-C)

    Time frame: 3 months

    Low-density lipoprotein cholesterol will be measured from fasting venous blood samples as part of a lipid panel. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  11. Change from baseline to 3 months in high-density lipoprotein cholesterol (HDL-C)

    Time frame: 3 months

    High-density lipoprotein cholesterol will be measured from fasting venous blood samples as part of a lipid panel. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  12. Change from baseline to 3 months in fasting triglyceride levels

    Time frame: 3 months

    Triglycerides will be measured from fasting venous blood samples as part of a lipid panel. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  13. Change from baseline to 3 months in fasting plasma glucose

    Time frame: 3 months

    Fasting glucose will be measured from venous blood samples collected during routine laboratory testing. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  14. Change from baseline to 3 months in creatinine

    Time frame: 3 months

    Creatinine will be measured from venous blood samples as part of a comprehensive metabolic panel to assess kidney function. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

  15. Change from baseline to 3 months in white blood cell count

    Time frame: 3 months

    White blood cell (WBC) count will be measured from venous blood samples as part of a complete blood count panel. Blood samples will be collected twice at baseline and twice during the final study period with assessments occurring at least 7 days apart. Measurements from each timepoint will be averaged.

Other outcomes

  1. Change in resting heart rate measured using wearable device data

    Time frame: 3 months

    Resting heart rate (beats per minute) will be measured using wearable device data averaged across a two-week period at baseline and at 3 months.

  2. Change in physical activity measured by metabolic equivalent of task (MET) minutes using Oura wearable device data

    Time frame: 3 months

    Physical activity will be assessed using metabolic equivalent of task (MET) estimates derived from wearable device activity data collected by the Oura Ring. MET minutes represent the intensity and duration of physical activity performed. MET data will be averaged across a two-week period at baseline and at 3 months. The outcome will be the change in average daily MET minutes from baseline to 3 months.

  3. Change in physiological stress score measured using Oura wearable device metric

    Time frame: 3 months

    Physiological stress will be assessed using the wearable device stress score derived from heart rate variability metrics. Stress data will be averaged across a two-week period at baseline and at 3 months. The outcome will be the change in physiological stress score from baseline to 3 months.

  4. Change in average daily step count measured using Oura wearable device

    Time frame: 3 months

    Physical activity will also be assessed using average daily step counts recorded by the Oura wearable device. Daily step count data will be averaged across a two-week period at baseline and at 3 months. The outcome will be the change in average daily step count from baseline to 3 months.

Sponsors and collaborators

Lead sponsor

AgelessRx

Industry

Registry information

Official study title

A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.